Takeda says first subject given Novavax COVID-19 vaccine in Japan clinical trial

Comments Off on Takeda says first subject given Novavax COVID-19 vaccine in Japan clinical trial
FILE PHOTO: A Novavax logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration

TOKYO (Reuters) – Takeda Pharmaceutical Co said on Wednesday the first subject had been given Novavax Inc’s COVID-19 vaccine candidate in a Japanese clinical trial.

Takeda has been contracted to handle the regulatory approvals for the vaccine in Japan. It will also manufacture and distribute up to 250 million doses of the vaccine candidate.

Source: Read Full Article

Related posts:
  1. Mexico approves emergency use of Sputnik V vaccine, official says
  2. South Africa halts AstraZeneca vaccinations over variant data
  3. China reports 14 new mainland COVID-19 cases, same as day earlier
  4. Philippines reports 239 new coronavirus deaths, second-highest daily casualty figure